Format

Send to

Choose Destination
Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Author information

1
Laboratory for Advanced Genome Analysis, Vancouver Prostate Centre, BC, Canada; Department of Urologic Sciences, University of British Columbia, BC, Canada; Department of Experimental Therapeutics, BC Cancer Agency, BC, Canada.
2
Department of Integrative Oncology, BC Cancer Agency, BC, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, BC, Canada.
3
Department of Pathology and Laboratory Medicine, University of British Columbia, BC, Canada.
4
Department of Urologic Sciences, University of British Columbia, BC, Canada; Department of Experimental Therapeutics, BC Cancer Agency, BC, Canada.
5
Laboratory for Advanced Genome Analysis, Vancouver Prostate Centre, BC, Canada; Department of Urologic Sciences, University of British Columbia, BC, Canada.
6
Italian Group for Research and Therapy for Mesothelioma (GIMe) & School of Environment and Life Sciences, University of Salford, Manchester, United Kingdom.

Abstract

Malignant mesotheliomas are aggressive, asbestos-related cancers with poor patient prognosis, typically arising in the mesothelial surfaces of tissues in pleural and peritoneal cavity. The relative unspecific symptoms of mesotheliomas, misdiagnoses, and lack of precise targeted therapies call for a more critical assessment of this disease. In the present review, we categorize commonly identified genomic aberrations of mesotheliomas into their canonical pathways and discuss targeting these pathways in the context of tumor hypoxia, a hallmark of cancer known to render solid tumors more resistant to radiation and most chemo-therapy. We then explore the concept that the intrinsic hypoxic microenvironment of mesotheliomas can be Achilles' heel for targeted, multimodal therapeutic intervention.

KEYWORDS:

DNA damage; angiogenesis; cell cycle; hypoxia; mesothelioma; metabolism; proteolysis; solid tumors

Conflict of interest statement

The authors confirm that there are no conflicts of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center